var data={"title":"Treatment protocols for small and large bowel cancer","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Treatment protocols for small and large bowel cancer</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-small-and-large-bowel-cancer/contributors\" class=\"contributor contributor_credentials\">Tim Brenner, PharmD, BCOP</a></dd><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-small-and-large-bowel-cancer/contributors\" class=\"contributor contributor_credentials\">Shrina Duggal, PharmD, BCOP</a></dd><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-small-and-large-bowel-cancer/contributors\" class=\"contributor contributor_credentials\">Jim Natale, PharmD, BCOP</a></dd><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-small-and-large-bowel-cancer/contributors\" class=\"contributor contributor_credentials\">Scott M Wirth, PharmD, BCOP</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-small-and-large-bowel-cancer/contributors\" class=\"contributor contributor_credentials\">John W Mucenski, PharmD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-small-and-large-bowel-cancer/contributors\" class=\"contributor contributor_credentials\">Diane MF Savarese, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-small-and-large-bowel-cancer/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Oct 27, 2016.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H15188773\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The following material represents a subset of chemotherapy regimens that are used for the treatment of patients with small bowel and colorectal cancer, both in the adjuvant setting and for advanced disease. <strong>This is</strong> <strong>not an exhaustive list</strong>; it includes regimens that are considered by the authors and editors to be commonly used and important for the care of patients with bowel cancer. Additional regimens may be added over time, particularly as treatment for colorectal cancer evolves.</p><p>This topic review is intended to provide only a listing of chemotherapy regimens. It does not address the appropriate context for use of these regimens in the care of patients with colorectal cancer. Clinicians should refer to the individual disease-oriented topic reviews that discuss the use of these protocols in appropriate clinical situations:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=systemic-chemotherapy-for-metastatic-colorectal-cancer-general-principles\" class=\"medical medical_review\">&quot;Systemic chemotherapy for metastatic colorectal cancer: General principles&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=systemic-chemotherapy-for-nonoperable-metastatic-colorectal-cancer-treatment-recommendations\" class=\"medical medical_review\">&quot;Systemic chemotherapy for nonoperable metastatic colorectal cancer: Treatment recommendations&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=therapy-for-metastatic-colorectal-cancer-in-elderly-patients-and-those-with-a-poor-performance-status\" class=\"medical medical_review\">&quot;Therapy for metastatic colorectal cancer in elderly patients and those with a poor performance status&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=management-of-potentially-resectable-colorectal-cancer-liver-metastases\" class=\"medical medical_review\">&quot;Management of potentially resectable colorectal cancer liver metastases&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=adjuvant-therapy-for-resected-stage-iii-node-positive-colon-cancer\" class=\"medical medical_review\">&quot;Adjuvant therapy for resected stage III (node-positive) colon cancer&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=adjuvant-chemotherapy-for-resected-stage-ii-colon-cancer\" class=\"medical medical_review\">&quot;Adjuvant chemotherapy for resected stage II colon cancer&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=adjuvant-therapy-for-resected-rectal-adenocarcinoma\" class=\"medical medical_review\">&quot;Adjuvant therapy for resected rectal adenocarcinoma&quot;</a>.)</p><p/><p>These tables are provided as examples of how to administer these regimens; there may be other acceptable methods. All chemotherapy regimens must be administered by clinicians who are trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary. </p><p>Treatment regimens for anal cancer are discussed separately. (See <a href=\"topic.htm?path=treatment-protocols-for-anal-cancer\" class=\"medical medical_review\">&quot;Treatment protocols for anal cancer&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H15188796\"><span class=\"h1\">REGIMENS</span></p><p class=\"headingAnchor\" id=\"H1223802151\"><span class=\"h2\">Chemotherapy</span></p><p class=\"headingAnchor\" id=\"H15189144\"><span class=\"h3\">Short-term infusional fluorouracil and leucovorin (modified de Gramont schedule)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F65525\" class=\"graphic graphic_table graphicRef65525 \">table 1</a>)</p><p class=\"headingAnchor\" id=\"H30672543\"><span class=\"h3\">Weekly bolus fluorouracil plus high-dose leucovorin (Roswell Park Memorial Institute [RPMI] regimen)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F86658\" class=\"graphic graphic_table graphicRef86658 \">table 2</a>)</p><p class=\"headingAnchor\" id=\"H333221303\"><span class=\"h3\">Capecitabine plus bevacizumab</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F94370\" class=\"graphic graphic_table graphicRef94370 \">table 3</a>)</p><p class=\"headingAnchor\" id=\"H15189229\"><span class=\"h3\">Modified FOLFOX6 (fluorouracil plus leucovorin and oxaliplatin)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F50132\" class=\"graphic graphic_table graphicRef50132 \">table 4</a>)</p><p class=\"headingAnchor\" id=\"H15189236\"><span class=\"h3\">Modified FOLFOX6 plus bevacizumab</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F62939\" class=\"graphic graphic_table graphicRef62939 \">table 5</a>)</p><p class=\"headingAnchor\" id=\"H15189243\"><span class=\"h3\">Modified FOLFOX7</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F55829\" class=\"graphic graphic_table graphicRef55829 \">table 6</a>)</p><p class=\"headingAnchor\" id=\"H15189250\"><span class=\"h3\">Modified FOLFOX7 plus bevacizumab</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F75802\" class=\"graphic graphic_table graphicRef75802 \">table 7</a>)</p><p class=\"headingAnchor\" id=\"H510321626\"><span class=\"h3\">Capecitabine plus oxaliplatin for small intestinal adenocarcinoma</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F96117\" class=\"graphic graphic_table graphicRef96117 \">table 8</a>)</p><p class=\"headingAnchor\" id=\"H932900316\"><span class=\"h3\">Capecitabine plus oxaliplatin (XELOX, CAPOX) for colorectal cancer</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F61781\" class=\"graphic graphic_table graphicRef61781 \">table 9</a>)</p><p class=\"headingAnchor\" id=\"H932900341\"><span class=\"h3\">XELOX/CAPOX plus bevacizumab for colorectal cancer</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F53192\" class=\"graphic graphic_table graphicRef53192 \">table 10</a>)</p><p class=\"headingAnchor\" id=\"H932900391\"><span class=\"h3\">FOLFIRI (fluorouracil plus leucovorin and irinotecan)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F76300\" class=\"graphic graphic_table graphicRef76300 \">table 11</a>)</p><p class=\"headingAnchor\" id=\"H932900416\"><span class=\"h3\">FOLFIRI plus bevacizumab</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F64505\" class=\"graphic graphic_table graphicRef64505 \">table 12</a>)</p><p class=\"headingAnchor\" id=\"H932900466\"><span class=\"h3\">FOLFOXIRI (fluorouracil plus leucovorin, oxaliplatin, and irinotecan)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F70559\" class=\"graphic graphic_table graphicRef70559 \">table 13</a>)</p><p class=\"headingAnchor\" id=\"H932900616\"><span class=\"h3\">Weekly single agent cetuximab</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F76312\" class=\"graphic graphic_table graphicRef76312 \">table 14</a>)</p><p class=\"headingAnchor\" id=\"H8791457\"><span class=\"h3\">Single agent panitumumab</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F86309\" class=\"graphic graphic_table graphicRef86309 \">table 15</a>)</p><p class=\"headingAnchor\" id=\"H15188984\"><span class=\"h3\">Cetuximab plus irinotecan</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F62096\" class=\"graphic graphic_table graphicRef62096 \">table 16</a>)</p><p class=\"headingAnchor\" id=\"H8791396\"><span class=\"h3\">FOLFIRI plus cetuximab</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F62726\" class=\"graphic graphic_table graphicRef62726 \">table 17</a>)</p><p class=\"headingAnchor\" id=\"H8791403\"><span class=\"h3\">FOLFIRI plus panitumumab</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F86311\" class=\"graphic graphic_table graphicRef86311 \">table 18</a>)</p><p class=\"headingAnchor\" id=\"H1223802299\"><span class=\"h2\">Concomitant chemoradiotherapy for rectal cancer</span></p><p class=\"headingAnchor\" id=\"H1223802247\"><span class=\"h3\">Concomitant chemoradiotherapy with capecitabine for rectal cancer in both the adjuvant and neoadjuvant setting</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F95632\" class=\"graphic graphic_table graphicRef95632 \">table 19</a>)</p><p class=\"headingAnchor\" id=\"H1223802253\"><span class=\"h3\">Concomitant chemoradiotherapy with infusional fluorouracil for rectal cancer in both the adjuvant and neoadjuvant setting</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F95677\" class=\"graphic graphic_table graphicRef95677 \">table 20</a>)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"topicVersionRevision\">Topic 85679 Version 13.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li><a href=\"#H15188773\" id=\"outline-link-H15188773\">INTRODUCTION</a></li><li><a href=\"#H15188796\" id=\"outline-link-H15188796\">REGIMENS</a><ul><li><a href=\"#H1223802151\" id=\"outline-link-H1223802151\">Chemotherapy</a><ul><li><a href=\"#H15189144\" id=\"outline-link-H15189144\">- Short-term infusional fluorouracil and leucovorin (modified de Gramont schedule)</a></li><li><a href=\"#H30672543\" id=\"outline-link-H30672543\">- Weekly bolus fluorouracil plus high-dose leucovorin (Roswell Park Memorial Institute [RPMI] regimen)</a></li><li><a href=\"#H333221303\" id=\"outline-link-H333221303\">- Capecitabine plus bevacizumab</a></li><li><a href=\"#H15189229\" id=\"outline-link-H15189229\">- Modified FOLFOX6 (fluorouracil plus leucovorin and oxaliplatin)</a></li><li><a href=\"#H15189236\" id=\"outline-link-H15189236\">- Modified FOLFOX6 plus bevacizumab</a></li><li><a href=\"#H15189243\" id=\"outline-link-H15189243\">- Modified FOLFOX7</a></li><li><a href=\"#H15189250\" id=\"outline-link-H15189250\">- Modified FOLFOX7 plus bevacizumab</a></li><li><a href=\"#H510321626\" id=\"outline-link-H510321626\">- Capecitabine plus oxaliplatin for small intestinal adenocarcinoma</a></li><li><a href=\"#H932900316\" id=\"outline-link-H932900316\">- Capecitabine plus oxaliplatin (XELOX, CAPOX) for colorectal cancer</a></li><li><a href=\"#H932900341\" id=\"outline-link-H932900341\">- XELOX/CAPOX plus bevacizumab for colorectal cancer</a></li><li><a href=\"#H932900391\" id=\"outline-link-H932900391\">- FOLFIRI (fluorouracil plus leucovorin and irinotecan)</a></li><li><a href=\"#H932900416\" id=\"outline-link-H932900416\">- FOLFIRI plus bevacizumab</a></li><li><a href=\"#H932900466\" id=\"outline-link-H932900466\">- FOLFOXIRI (fluorouracil plus leucovorin, oxaliplatin, and irinotecan)</a></li><li><a href=\"#H932900616\" id=\"outline-link-H932900616\">- Weekly single agent cetuximab</a></li><li><a href=\"#H8791457\" id=\"outline-link-H8791457\">- Single agent panitumumab</a></li><li><a href=\"#H15188984\" id=\"outline-link-H15188984\">- Cetuximab plus irinotecan</a></li><li><a href=\"#H8791396\" id=\"outline-link-H8791396\">- FOLFIRI plus cetuximab</a></li><li><a href=\"#H8791403\" id=\"outline-link-H8791403\">- FOLFIRI plus panitumumab</a></li></ul></li><li><a href=\"#H1223802299\" id=\"outline-link-H1223802299\">Concomitant chemoradiotherapy for rectal cancer</a><ul><li><a href=\"#H1223802247\" id=\"outline-link-H1223802247\">- Concomitant chemoradiotherapy with capecitabine for rectal cancer in both the adjuvant and neoadjuvant setting</a></li><li><a href=\"#H1223802253\" id=\"outline-link-H1223802253\">- Concomitant chemoradiotherapy with infusional fluorouracil for rectal cancer in both the adjuvant and neoadjuvant setting</a></li></ul></li></ul></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ONC/85679|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ONC/65525\" class=\"graphic graphic_table\">- Modified de Gramont schedule for gastrointestinal cancer</a></li><li><a href=\"image.htm?imageKey=ONC/86658\" class=\"graphic graphic_table\">- Weekly fluorouracil plus leucovorin for colorectal cancer</a></li><li><a href=\"image.htm?imageKey=ONC/94370\" class=\"graphic graphic_table\">- Capecitabine and bevacizumab elderly mCRC</a></li><li><a href=\"image.htm?imageKey=ONC/50132\" class=\"graphic graphic_table\">- Modified FOLFOX6</a></li><li><a href=\"image.htm?imageKey=ONC/62939\" class=\"graphic graphic_table\">- Modified FOLFOX6 plus bevacizumab chemotherapy</a></li><li><a href=\"image.htm?imageKey=ONC/55829\" class=\"graphic graphic_table\">- Modified FOLFOX7 regimen</a></li><li><a href=\"image.htm?imageKey=ONC/75802\" class=\"graphic graphic_table\">- Modified FOLFOX7 plus bevacizumab chemotherapy</a></li><li><a href=\"image.htm?imageKey=ONC/96117\" class=\"graphic graphic_table\">- CAPOX small intestinal adenocarcinoma</a></li><li><a href=\"image.htm?imageKey=ONC/61781\" class=\"graphic graphic_table\">- CAPOX regimen for colorectal cancer</a></li><li><a href=\"image.htm?imageKey=ONC/53192\" class=\"graphic graphic_table\">- CAPOX plus bevacizumab regimen</a></li><li><a href=\"image.htm?imageKey=ONC/76300\" class=\"graphic graphic_table\">- FOLFIRI regimen</a></li><li><a href=\"image.htm?imageKey=ONC/64505\" class=\"graphic graphic_table\">- FOLFIRI plus bevacizumab</a></li><li><a href=\"image.htm?imageKey=ONC/70559\" class=\"graphic graphic_table\">- FOLFOXIRI</a></li><li><a href=\"image.htm?imageKey=ONC/76312\" class=\"graphic graphic_table\">- Cetuximab monotherapy colorectal cancer</a></li><li><a href=\"image.htm?imageKey=ONC/86309\" class=\"graphic graphic_table\">- Panitumumab monotherapy CRC</a></li><li><a href=\"image.htm?imageKey=ONC/62096\" class=\"graphic graphic_table\">- Cetuximab plus irinotecan for colorectal cancer</a></li><li><a href=\"image.htm?imageKey=ONC/62726\" class=\"graphic graphic_table\">- FOLFIRI plus cetuximab for colorectal cancer</a></li><li><a href=\"image.htm?imageKey=ONC/86311\" class=\"graphic graphic_table\">- FOLFIRI plus panitumumab for colorectal cancer</a></li><li><a href=\"image.htm?imageKey=ONC/95632\" class=\"graphic graphic_table\">- Capecitabine XRT rectal</a></li><li><a href=\"image.htm?imageKey=ONC/95677\" class=\"graphic graphic_table\">- Fluorouracil XRT rectal</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=adjuvant-chemotherapy-for-resected-stage-ii-colon-cancer\" class=\"medical medical_review\">Adjuvant chemotherapy for resected stage II colon cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=adjuvant-therapy-for-resected-rectal-adenocarcinoma\" class=\"medical medical_review\">Adjuvant therapy for resected rectal adenocarcinoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=adjuvant-therapy-for-resected-stage-iii-node-positive-colon-cancer\" class=\"medical medical_review\">Adjuvant therapy for resected stage III (node-positive) colon cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-potentially-resectable-colorectal-cancer-liver-metastases\" class=\"medical medical_review\">Management of potentially resectable colorectal cancer liver metastases</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=systemic-chemotherapy-for-metastatic-colorectal-cancer-general-principles\" class=\"medical medical_review\">Systemic chemotherapy for metastatic colorectal cancer: General principles</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=systemic-chemotherapy-for-nonoperable-metastatic-colorectal-cancer-treatment-recommendations\" class=\"medical medical_review\">Systemic chemotherapy for nonoperable metastatic colorectal cancer: Treatment recommendations</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=therapy-for-metastatic-colorectal-cancer-in-elderly-patients-and-those-with-a-poor-performance-status\" class=\"medical medical_review\">Therapy for metastatic colorectal cancer in elderly patients and those with a poor performance status</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-protocols-for-anal-cancer\" class=\"medical medical_review\">Treatment protocols for anal cancer</a></li></ul></div></div>","javascript":null}